LATIN AMERICA IMMUNOGLOBULIN MARKET 2022-2028
TABLE OF CONTENTS
1.
LATIN AMERICA
IMMUNOGLOBULIN MARKET – SUMMARY
2.
INDUSTRY
OUTLOOK
2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY INSIGHTS
2.2.1.
DEVELOPMENT OF
NEW PURIFICATION METHODS
2.2.2.
INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1.
THREAT OF NEW
ENTRANTS
2.3.2.
THREAT OF
SUBSTITUTES
2.3.3.
BARGAINING
POWER OF BUYERS
2.3.4.
BARGAINING
POWER OF SUPPLIERS
2.3.5.
THREAT OF
COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. KEY MARKET STRATEGIES
2.6.1.
PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2.
PARTNERSHIPS
& AGREEMENTS
2.7. MARKET DRIVERS
2.7.1.
GROWTH IN THE
GERIATRIC POPULATION
2.7.2.
PREVALENCE OF
IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3.
INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET CHALLENGES
2.8.1.
HIGH COST OF
THERAPY
2.8.2.
HIGH RISK OF
SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET OPPORTUNITIES
2.9.1.
INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2.
GROWING
CLINICAL TRIALS
3.
LATIN AMERICA
IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4.
LATIN AMERICA
IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5.
LATIN AMERICA
IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA GLOBULINEMIA
5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA GRAVIS
5.5. MULTIFOCAL MOTOR NEUROPATHY
5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY MYOPATHIES
5.8. SPECIFIC ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE SYNDROME
5.10.
OTHER
APPLICATIONS
6.
LATIN AMERICA
IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS & CLINICS
6.2. HOMECARE
7.
LATIN AMERICA
IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL PHARMACY
7.2. SPECIALTY PHARMACY
7.3. OTHER SALES CHANNELS
8.
LATIN AMERICA
IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. BRAZIL
8.2. MEXICO
8.3. REST OF LATIN AMERICA
9.
COMPETITIVE LANDSCAPE
9.1. BIOTEST AG
9.2. CHINA BIOLOGIC PRODUCTS INC
9.3. GRIFOLS SA
9.4. LFB GROUP
9.5. CSL BEHRING
9.6. KEDRION BIOPHARMA
9.7. OCTAPHARMA AG
9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.9. BIO PRODUCTS LABORATORY
9.10.
SHANGHAI RAAS
BLOOD PRODUCTS CO LTD
9.11.
PFIZER INC
9.12.
SANQUIN PLASMA
PRODUCTS BV
9.13.
ADMA BIOLOGICS
9.14.
SICHUAN YUANDA
SHUYANG PHARMACEUTICAL CO LTD
9.15.
KAMADA LTD
10. RESEARCH METHODOLOGY & SCOPE
10.1.
RESEARCH SCOPE
& DELIVERABLES
10.2.
SOURCES OF
DATA
10.3.
RESEARCH
METHODOLOGY
TABLE LIST
TABLE 1: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR
SCORECARD
TABLE 3: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE LIST
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: LATIN AMERICA
IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $
MILLION)
FIGURE 14: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 15: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028
(IN $ MILLION)
FIGURE 16: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $
MILLION)
FIGURE 18: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),
2022-2028 (IN $ MILLION)
FIGURE 19: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $
MILLION)
FIGURE 20: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $
MILLION)
FIGURE 22: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $
MILLION)
FIGURE 25: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: LATIN
AMERICA IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $
MILLION)
FIGURE 30: LATIN
AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: BRAZIL
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: MEXICO
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: REST OF
LATIN AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
Favorable and supportive initiatives by the government facilitate the growth
of Latin America’s immunoglobulin market
MARKET OUTLOOK
The Latin America
immunoglobulin market is speculated to exhibit growth with a CAGR of 5.29% over
the forecasting years 2022-2028, states a Triton Market Research report.
Mexico, Brazil, and Rest of Latin America are assessed in the market in this
region.
In Mexico, the
immunoglobulin market’s growth is accelerating due to increasing government
approvals, rising research & development activities, and new product
launches. For instance, Mexico’s health regulator Cofepris allowed antibody
treatment of Eli Lilly and Co against COVID-19 to treat comorbidities patients
in emergency. This has significantly influenced other market players to tap
innovation into the market through research & development activities. This
is expected to bolster the growth of the studied market in the coming years.
The support from the
Brazilian government and the deployment of strategic initiatives by market
players have significantly aided in the development of immunoglobulin products.
For instance, the Brazilian Health Regulatory Agency granted authorization for
Celltrion Healthcare’s regdanvimab for emergency use. It is a monoclonal
antibody treatment to treat patients with mild-to-moderate COVID-19. Likewise,
in 2019, SK Plasma won a $20 million bid to supply LIV-Gamma, a human
immunoglobulin, to the Brazil Ministry of Health. These factors are expected to
promote the growth of the considered market over the forthcoming period.
Get more insights into the Latin America Immunoglobulin Market:
https://www.tritonmarketresearch.com/reports/latin-america-immunoglobulin-market
COMPETITIVE OUTLOOK
The top players in the immunoglobulin
market are China Biologic Products Inc, Octapharma AG, Kedrion Biopharma, CSL
Behring, Pfizer Inc, Grifols SA, LFB Group, Sichuan Yuanda Shuyang
Pharmaceutical Co Ltd, Takeda Pharmaceutical Company Limited, and Shanghai RAAS
Blood Products Co Ltd.
SEGMENTATION
1.
BIOTEST AG
2.
CHINA BIOLOGIC
PRODUCTS INC
3.
GRIFOLS SA
4.
LFB GROUP
6.
KEDRION
BIOPHARMA
7.
OCTAPHARMA AG
8.
TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.
BIO PRODUCTS
LABORATORY
10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
11. PFIZER INC
12. SANQUIN PLASMA PRODUCTS BV
13. ADMA BIOLOGICS
14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
15. KAMADA LTD
Comments
Post a Comment